New buprenorphine wafers could help thousands battling opioid addiction
When compared with current hard sublingual tablets, the novel formulation dissolved quickly with no increased safety concerns and no demonstrable difference in efficacy.
Martindale Pharma has announced results from a Phase II randomised study published in European Addiction Research on Espranor – the rapidly dissolving oral lyophilisate formulation of buprenorphine. Data on this unique opioid substitution therapy (OST) show that, when compared with current hard sublingual (under the tongue) tablets, the novel formulation dissolved quickly with no increased safety concerns and no demonstrable difference in efficacy. Espranor represents the first major advance in OST for 10 years. With tens of thousands of people across the UK suitable for treatment with buprenorphine, data such as these may support wider prescribing, improved care and reduced burden on healthcare providers who supervise OST.
“Buprenorphine plays a vital role in opioid substitution therapy for many patients. However, it is recognised that a significant barrier has been the time-consuming and often stigmatising process of supervising its administration,” said Dr Baillie, Group Medical Director of Martindale Pharma. “These data demonstrate that using this rapidly-dissolving formulation of buprenorphine may offer practical benefits without compromising safety or efficacy.”
The study assessed the safety of the new buprenorphine oral lyophilisate wafer versus standard sublingual buprenorphine tablets, (Subutex). Patients were opioid-dependent, commencing buprenorphine maintenance and were treated in a specialised clinical trials or addictions treatment facility. Results showed that 96.3% of Espranor administrations achieved partial disintegration on the tongue within 15 seconds, meaning at this time point the wafer could no longer be removed from the mouth intact. Overall the median time to complete disintegration of the Espranor wafer was two minutes compared with 10 minutes for standard sublingual buprenorphine tablets (p< 0.0001). There were no significant between-group differences in opiate-withdrawal phenomena, craving or adequacy of “hold,” or respiratory function. No serious adverse events (AEs) were observed. Although more mild AEs and treatment-emergent AEs were observed with the wafer formulation, all events were transient and self-limiting. Pharmacokinetic analysis found greater bioavailability of buprenorphine but not nor-buprenorphine with Espranor.
“It is vital that we find better ways of supporting people across the UK battling opioid addiction,” said Annemarie Ward, CEO of Faces and Voices of Recovery. “These results are promising as they indicate that, by just using a simpler form of buprenorphine, we may increase its use and reduce some of the problems seen with conventional pills. Having another choice of treatment available is always a cause for celebration. The challenge now will be to explore how we help those on the front lines of OST understand how and when it should be used.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance